Niagen Bioscience (NAGE) reported $129M in revenue for fiscal 2025, +29.9% year on year. That ranks #2840 by revenue among 2853 SEC filers and #320 in Healthcare. Net income was $17.4M, a net margin of 13.4%. Revenue has grown 25.4% a year on average since 2017 ($21.2M then). The fiscal 2025 balance sheet shows $106M in total assets, $64.8M in cash and $0 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $129M | +29.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $83.2M | +35.1% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | $16.3M | +110.7% | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $17.4M | +103.3% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $13.5M | +11.5% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $743,000 | −43.8% | FY20192019-12-31 |
| Total assetsAssets | $106M | +55.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $76.5M | +66.0% | FY20252025-12-31 |
| CashCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | $64.8M | +45.6% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $0 | −100.0% | FY20162016-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $31.5M | $6.3M | Open → |
| Q2 20262026-06-30 | $29.8M | $963,000 | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Niagen Bioscience, Inc.
- Ticker
- NAGE
- Exchange
- Nasdaq
- SIC classification
- Medicinal Chemicals & Botanical Products (2833)
- Fiscal year end
- 12-31
- CIK
- 0001386570
Filings
- 10-QAug 4, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KMar 4, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Xtant MedicalXTNT | $134M | $4,973 |
| RidgetechRDGT | $132M | −$1.3M |
| Natural Alternatives InternationalNAII | $130M | −$13.6M |
| Niagen BioscienceNAGE | $129M | $17.4M |
| XencorXNCR | $126M | −$91.9M |
| Monte Rosa TherapeuticsGLUE | $124M | −$38.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Niagen Bioscience — Key figures |url=https://companiesranked.com/en/company/niagen-bioscience |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Niagen Bioscience — Key figures. CompaniesRanked. https://companiesranked.com/en/company/niagen-bioscienceBibTeX
@misc{companiesranked-en-company-niagen-bioscience-2026,
author = {{CompaniesRanked}},
title = {{Niagen Bioscience — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/niagen-bioscience}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001386570-26-000013 · March 4, 2026
{{cite web |title=Niagen Bioscience — Key figures — 10-K (0001386570-26-000013) |url=https://www.sec.gov/Archives/edgar/data/1386570/000138657026000013/cdxc-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-04}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.